Evidence map›Paper›PMID 40999784›Full record

ArticleAngewandte Chemie (International ed. in English)2025

Sulfinyl Aziridines as Stereoselective Covalent Destabilizing Degraders of the Oncogenic Transcription Factor MYC.

Hannah T Rosen, Kelvin Li, Christian E Stieger, Erin L Li, Brynne Currier, Scott M Brittain, Francisco J Garcia, Diana C Beard, Michael D Jones, Sandra Haenni-Holzinger and 5 more

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Hannah T Rosen *Department of Chemistry, University of California, Berkeley, Berkeley, CA, 94720, USA.
Kelvin Li *Department of Chemistry, University of California, Berkeley, Berkeley, CA, 94720, USA.
Christian E StiegerDepartment of Chemistry, University of California, Berkeley, Berkeley, CA, 94720, USA.
Erin L LiDepartment of Chemistry, University of California, Berkeley, Berkeley, CA, 94720, USA.
Brynne CurrierDepartment of Chemistry, University of California, Berkeley, Berkeley, CA, 94720, USA.
Scott M BrittainNovartis-Berkeley Translational Chemical Biology Institute, Berkeley, CA, 94720, USA.
Francisco J GarciaNovartis-Berkeley Translational Chemical Biology Institute, Berkeley, CA, 94720, USA.
Diana C BeardNovartis-Berkeley Translational Chemical Biology Institute, Berkeley, CA, 94720, USA.
Michael D JonesNovartis-Berkeley Translational Chemical Biology Institute, Berkeley, CA, 94720, USA.
Sandra Haenni-HolzingerNovartis-Berkeley Translational Chemical Biology Institute, Berkeley, CA, 94720, USA.
Dustin DovalaNovartis-Berkeley Translational Chemical Biology Institute, Berkeley, CA, 94720, USA.
Jeffrey M McKennaNovartis-Berkeley Translational Chemical Biology Institute, Berkeley, CA, 94720, USA.
Markus SchirleNovartis-Berkeley Translational Chemical Biology Institute, Berkeley, CA, 94720, USA.
Thomas J MaimoneDepartment of Chemistry, University of California, Berkeley, Berkeley, CA, 94720, USA.
Daniel K NomuraDepartment of Chemistry, University of California, Berkeley, Berkeley, CA, 94720, USA.ORCID 0000-0003-1614-8360

Funding

Chemical Approaches to Modulate PAX3-FOXO1 in Fusion-Positive Alveolar RhabdomyosarcomaUM1CA294108 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ALEX B BURGIN, Alexandra E Gould · 2024 to 2026
$6.9M
Tackling Undruggable Cancer Targets using Chemoproteomic PlatformsR35CA263814 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI Daniel Nomura · 2022 to 2026
$4.6M
Harnessing E3 Ligases for Cancer TherapyR01CA240981 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI Daniel Nomura · 2019 to 2026
$4.3M
Barbara and Gerson Bakar FoundationMark Foundation For Cancer ResearchNational Science Foundation 2127788NCI NIH HHS R01 CA240981NCI NIH HHS R35 CA263814NCI NIH HHS UM1 CA294108NIH HHS R01CA240981NIH HHS R35CA263814NIH HHS UM1CA29410Novartis Institutes for BioMedical Research
6 · The paper itself

Abstract

Although MYC is a significant oncogenic transcription factor driver of cancer, directly targeting MYC has remained challenging due to its intrinsic disorder and poorly defined structure, deeming it "undruggable." Whether transient pockets formed within unstructured regions of proteins can be selectively targeted with small molecules remains an outstanding challenge. Here, we developed a stereochemically paired spirocyclic oxindole aziridine covalent library and screened this library for degradation of MYC. We identified a hit covalent ligand, KL2-236, bearing a unique sulfinyl aziridine warhead, that engaged MYC as a pure MYC/MAX protein complex, and in cancer cells to destabilize MYC, inhibit MYC transcriptional activity and degrade MYC in a proteasome-dependent manner through targeting intrinsically disordered C203 and D205 residues. Notably, this reactivity was most pronounced for specific stereoisomers of KL2-236 with a diastereomer, KL4-019, that was largely inactive. Mutagenesis of both C203 and D205 completely attenuated KL2-236-mediated MYC degradation. We also optimized our KL2-236 hit compound to generate a more potent, selective, and durable MYC degrader, KL4-219A. Our results reveal a novel ligandable site within MYC and indicate that certain intrinsically disordered regions within transcription factors, such as MYC, can be interrogated by isomerically unique chiral small molecules, leading to destabilization and degradation.

Indexed as

AziridinesProto-Oncogene Proteins c-mycCell Line, TumorHumansMolecular StructureStereoisomerismAziridinesMYC protein, humanProto-Oncogene Proteins c-mycActivity‐based protein profilingChemoproteomicsCovalentCysteineMYCSulfinyl aziridineTargeted protein degradation

Identifiers

PMID40999784
PMCPMC13157644

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.